FemasysFEMY -1.91%55 OCF Margin % is -975.06% as of Mar. 2026. GuruFocus rates FEMY with a GF Score™ of 55/100 and a GF Value™ of $12.23 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Femasys ranks worse than 93.87% on this metric.
The historical rank and industry rank for Femasys's OCF Margin % or its related term are showing as below:
FEMY'
s OCF Margin % Range Over the Past 10 Years
Min: -1193.62 Med: -889.88 Max: -475.24
Current: -760.48
During the past 7 years, the highest OCF Margin % of Femasys was -475.24%. The lowest was -1193.62%. And the median was -889.88%.
FEMY's OCF Margin % is ranked worse than 93.87% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.86
vs FEMY: -760.48
Femasys OCF Margin % Related Terms
Femasys OCF Margin % Historical Data
* Premium members only.
The historical data trend for Femasys's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Femasys's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Femasys OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Femasys's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Femasys's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Femasys (FEMY) has a OCF Margin % of -975.06% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Femasys and its competitors. According to the industry distribution chart, Femasys ranks #765 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 93.9%.
Is Femasys' OCF Margin % too high?
Femasys' current OCF Margin % is -975.06%. Based on the distribution chart, Femasys ranks #765 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Femasys has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Femasys' OCF Margin % compare to RVP and HBIO?
According to the Medical Devices & Instruments industry distribution chart, Femasys ranks #765 out of 815 companies for OCF Margin %. This places Femasys in the lower half of its industry. The industry median OCF Margin % is 5.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Femasys and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Femasys's current OCF Margin % is -975.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Femasys stock overvalued right now?
Based on GuruFocus' analysis, Femasys (FEMY) is currently considered Possible Value Trap. The stock's GF Value™ is $12.23, compared to a current price of $3.60 — trading 70.6% below its estimated fair value. The current OCF Margin % is -975.06%. Femasys' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Femasys (FEMY), the current OCF Margin % is -975.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Femasys (FEMY) Overvalued in 2026?
Based on GuruFocus' analysis, Femasys stock appears to be undervalued.
The current stock price of $3.60 is trading 70.6% below its estimated GF Value™ of $12.23.
GuruFocus considers Femasys to be Possible Value Trap.
Key valuation signals for FEMY:
OCF Margin %: -975.06%
GF Value™: $12.23 vs. price of $3.60 (70.6% below fair value)
No single metric tells the full story. See the FEMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
55GF Score
Get the complete analysis for FEMY
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FEMY has been successfully added to your 
